The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
复制标题
DOI：
10.1186/s12883-014-0254-4
复制
发表时间：
2014-12-31
期刊：
影响因子：
2.6
通讯作者：
van der Flier, Wiesje M.
中科院分区：
文献类型：
--
作者：
Aalten, Pauline;Ramakers, Inez H. G. B.;van der Flier, Wiesje M.
背景资料：Parelsnoer研究所是8个荷兰大学医学中心之间的合作，根据协调的协议收集慢性疾病患者的临床数据和生物材料（所谓的“珍珠”）。Pearl神经退行性疾病专注于生物标志物在早期诊断，鉴别诊断和监测神经退行性疾病，特别是阿尔茨海默病过程中的作用。本文的目的是描述的设计和方法的珍珠神经退行性疾病，以及基线描述性变量，包括其生物标志物profile.Methods：珍珠神经退行性疾病是一个为期3年的后续研究的患者提到的记忆诊所与认知投诉。在基线时，所有患者均接受标准化检查，包括临床数据和生物库材料，例如血液样本、MRI和脑脊液。目前，共有1000多名患者被纳入，其中211名和661名患者的脑脊液和DNA样本分别可用。数据的子样本（n = 665）的第一次抽样显示，患者被诊断为痴呆（45%），轻度认知障碍（31%），和主观记忆投诉（24%）。讨论：珍珠神经退行性疾病是一个正在进行的大型网络收集临床数据和生物材料的1000多名患者的认知障碍。该项目从基线特征和生物标志物的数据分析开始，这将是未来可以通过这个独特的数据集回答的具体研究问题的起点。
Background: The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical data and biomaterials from patients suffering from chronic diseases (so called "Pearls") are collected according to harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis, differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer's disease. The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as baseline descriptive variables, including their biomarker profile.Methods: The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients, respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%).Discussion: The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and biomaterials of more than 1000 patients with cognitive impairments. The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset.